Patents by Inventor Makoto Fushimi
Makoto Fushimi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11236099Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.Type: GrantFiled: June 19, 2018Date of Patent: February 1, 2022Assignee: Takeda Pharmaceutical Company LimitedInventors: Kazuaki Takami, Masaki Seto, Shinobu Sasaki, Haruhi Ando, Masaki Ogino, Tomoko Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Yasuhiro Tsukimi, Masami Yamada, Kenichiro Shimokawa, Takeshi Wakabayashi, Masataka Murakami, Makoto Fushimi, Tomohiro Okawa, Jinichi Yonemori, Tomohiro Ohashi, Hideo Suzuki, Hironobu Maezaki, Ayumu Sato, Yasutomi Asano, Steve Swann
-
Publication number: 20220017530Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.Type: ApplicationFiled: September 15, 2021Publication date: January 20, 2022Applicant: Takeda Pharmaceutical Company LimitedInventors: Kazuaki Takami, Masaki Seto, Shinobu Sasaki, Haruhi Ando, Masaki Ogino, Tomoko Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Yasuhiro Tsukimi, Masami Yamada, Kenichiro Shimokawa, Takeshi Wakabayashi, Masataka Murakami, Makoto Fushimi, Tomohiro Okawa, Jinichi Yonemori, Tomohiro Ohashi, Hideo Suzuki, Hironobu Maezaki, Ayumu Sato, Yasutomi Asano, Steve Swann
-
Publication number: 20210353607Abstract: The development of a new, targeted drug delivery paradigm coupled to improved PI3K inhibitors (e.g., PI3K? inhibitors) represents a significant advance in cancer therapy. Provided herein are compounds, such as compounds of Formula (I) and (II), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The compounds provided herein are PI3K (e.g., PI3K?) inhibitors and are therefore useful for the treatment and/or prevention of various diseases (e.g., proliferative diseases such as cancer). Also provided herein are nanoparticles and nanogels (e.g., P-selectin targeting nanoparticles) comprising PI3K inhibitors, such a compound described herein. In certain embodiments, a nanoparticle or nanogel described herein encapsulates a compound described herein for targeting delivery to cancer cells or tumors.Type: ApplicationFiled: October 4, 2019Publication date: November 18, 2021Applicants: Sloan-Kettering Institute for Cancer Research, Tri-lnstitutional Therapeutics Discovery Institute, Inc.Inventors: Makoto Fushimi, Maurizio Scaltriti, Daniel Alan Heller, Carles Monterrubio Martinez, Amaia Arruabarrena Aristorena, Peter T. Meinke, Michael Andrew Foley, Yasutomi Asano, Kazuyoshi Aso, Hiroki Takahagi, Yosef Shamay, Jose Manuel Baselga Torres, Yusuke Sasaki, Mayako Michino
-
Publication number: 20210139491Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.Type: ApplicationFiled: June 19, 2018Publication date: May 13, 2021Inventors: Kazuaki TAKAMI, Masaki SETO, Shinobu SASAKI, Haruhi ANDO, Masaki OGINO, Tomoko OHASHI, Toshihiro IMAEDA, Ikuo FUJIMORI, Yasuhiro TSUKIMI, Masami YAMADA, Kenichiro SHIMOKAWA, Takeshi WAKABAYASHI, Masataka MURAKAMI, Makoto FUSHIMI, Tomohiro OKAWA, Jinichi YONEMORI, Tomohiro OHASHI, Hideo SUZUKI, Hironobu MAEZAKI, Ayumu SATO, Yasutomi ASANO, Steve SWANN
-
Patent number: 10794639Abstract: A cooling structure includes a plurality of heat radiation parts configured to cool a heat generating component and a holding member configured to hold the plurality of heat radiation parts. Moreover, the heat radiation parts of the cooling structure each include a base portion located on the side of the heat generating component and a fin portion extending from the base portion and radiating heat. Furthermore, the base portions of the heat radiation parts abut on each other.Type: GrantFiled: March 4, 2019Date of Patent: October 6, 2020Assignee: NEC CORPORATIONInventor: Makoto Fushimi
-
Patent number: 10548877Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.Type: GrantFiled: March 9, 2017Date of Patent: February 4, 2020Assignee: Takeda Pharmaceutical Company LimitedInventors: Masaki Ogino, Eiji Kimura, Shinkichi Suzuki, Kouji Fuji, Tomohiro Ohashi, Makoto Fushimi, Kei Masuda, Tatsuki Koike, Takeshi Wakabayashi, Jinichi Yonemori, Masami Yamada
-
Publication number: 20190285362Abstract: A cooling structure includes a plurality of heat radiation parts configured to cool a heat generating component and a holding member configured to hold the plurality of heat radiation parts. Moreover, the heat radiation parts of the cooling structure each include a base portion located on the side of the heat generating component and a fin portion extending from the base portion and radiating heat. Furthermore, the base portions of the heat radiation parts abut on each other.Type: ApplicationFiled: March 4, 2019Publication date: September 19, 2019Applicant: NEC CorporationInventor: Makoto FUSHIMI
-
Publication number: 20190083467Abstract: Provided is a compound having a cholinergic muscarine M1 receptor positive allosteric modulator activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a cholinergic muscarine M1 receptor positive allosteric modulator activity, and is useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like.Type: ApplicationFiled: March 9, 2017Publication date: March 21, 2019Inventors: Masaki OGINO, Eiji KIMURA, Shinkichi SUZUKI, Kouji FUJI, Tomohiro OHASHI, Makoto FUSHIMI, Kei MASUDA, Tatsuki KOIKE, Takeshi WAKABAYASHI, Jinichi YONEMORI, Masami YAMADA
-
Patent number: 10202376Abstract: Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.Type: GrantFiled: December 21, 2015Date of Patent: February 12, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Eiji Kimura, Yuhei Miyanohana, Masaki Ogino, Yuta Tanaka, Makoto Fushimi, Tomohiro Okawa, Yuki Hanya, Tatsuki Koike
-
Patent number: 10106556Abstract: The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.Type: GrantFiled: March 29, 2016Date of Patent: October 23, 2018Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Shuhei Ikeda, Tatsuki Koike, Jumpei Aida, Makoto Fushimi, Tomokazu Kusumoto, Hideyuki Sugiyama, Masako Miyazaki, Hidekazu Tokuhara, Yasushi Hattori, Makoto Kamata
-
Publication number: 20180233459Abstract: A first substrate, a second substrate, and a retaining member are included. On the first substrate, a heat-generating part is mounted. The second substrate is connected to the first substrate via a connection member. The retaining member is configured to retain a height between the first substrate and the second substrate and is placed on a surface of the first substrate other than a surface facing the second substrate.Type: ApplicationFiled: December 5, 2017Publication date: August 16, 2018Applicant: NEC CorporationInventor: Makoto Fushimi
-
Publication number: 20180079756Abstract: The present invention provides a compound having an MAGL inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like. The present invention relates a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.Type: ApplicationFiled: March 29, 2016Publication date: March 22, 2018Inventors: Shuhei IKEDA, Tatsuki KOIKE, Jumpei AIDA, Makoto FUSHIMI, Tomokazu KUSUMOTO, Hideyuki SUGIYAMA, Masako MIYAZAKI, Hidekazu TOKUHARA, Yasushi HATTORI, Makoto KAMATA
-
Publication number: 20170362223Abstract: Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.Type: ApplicationFiled: December 21, 2015Publication date: December 21, 2017Applicant: Takeda Pharmaceutical Company LimitedInventors: Eiji KIMURA, Yuhei MIYANOHANA, Masaki OGINO, Yuta TANAKA, Makoto FUSHIMI, Tomohiro OKAWA, Yuki HANYA, Tatsuki KOIKE
-
Publication number: 20170114044Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0) wherein R1 represents a substituent, R2 represents a hydrogen atom, or a substituent, R3 represents a hydrogen atom, or a substituent, Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.Type: ApplicationFiled: December 13, 2016Publication date: April 27, 2017Inventors: Takahiko TANIGUCHI, Akira KAWADA, Mitsuyo KONDO, John F. QUINN, Jun KUNITOMO, Masato YOSHIKAWA, Makoto FUSHIMI
-
Patent number: 9624170Abstract: The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis and the like), anxiety disorder, pain (e.g., inflammatory pain, carcinomatous pain, nervous pain and the like), epilepsy and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: GrantFiled: December 25, 2014Date of Patent: April 18, 2017Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Tatsuki Koike, Makoto Fushimi, Jumpei Aida, Shuhei Ikeda, Tomokazu Kusumoto, Hideyuki Sugiyama, Hidekazu Tokuhara
-
Patent number: 9550756Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0): wherein R1 represents a substituent, R2 represents a hydrogen atom, or a substituent, R3 represents a hydrogen atom, or a substituent, Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.Type: GrantFiled: October 17, 2014Date of Patent: January 24, 2017Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Takahiko Taniguchi, Jun Kunitomo, Masato Yoshikawa, Makoto Fushimi
-
Publication number: 20160318864Abstract: The present invention aims to provide a compound having an MAGL inhibitory action, and useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis and the like), anxiety disorder, pain (e.g., inflammatory pain, carcinomatous pain, nervous pain and the like), epilepsy and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.Type: ApplicationFiled: December 25, 2014Publication date: November 3, 2016Inventors: Tatsuki KOIKE, Makoto FUSHIMI, Jumpei AIDA, Shuhei IKEDA, Tomokazu KUSUMOTO, Hideyuki SUGIYAMA, Hidekazu TOKUHARA
-
Patent number: 9150588Abstract: A compound having PDE inhibitory represented by formula (1), W1-W2 (1), wherein (i) W1 is and W2 is (ii) W1 is and W2 is or (iii) W1 is and W2 is or a pharmaceutically acceptable salt thereof; and a method of treating or preventing schizophrenia.Type: GrantFiled: August 9, 2011Date of Patent: October 6, 2015Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Takahiko Taniguchi, Masato Yoshikawa, Tomoaki Hasui, Makoto Fushimi, Jun Kunitomo
-
Patent number: 9090586Abstract: The present invention provides a compound represented by the formula (1): wherein each symbol is as defined in the specification, or a salt thereof, a prodrug of the compound or a salt thereof, a medicament containing the compound or a salt thereof, the medicament which is a phosphodiesterase 10A inhibitor, and a medicament which is for preventing or treating schizophrenia.Type: GrantFiled: August 3, 2011Date of Patent: July 28, 2015Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Masato Yoshikawa, Shinkichi Suzuki, Tomoaki Hasui, Makoto Fushimi, Jun Kunitomo, Haruhi Kamisaki, Takahiko Taniguchi
-
Publication number: 20150099757Abstract: The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I0): wherein R1 represents a substituent, R2 represents a hydrogen atom, or a substituent, R3 represents a hydrogen atom, or a substituent, Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.Type: ApplicationFiled: October 17, 2014Publication date: April 9, 2015Inventors: Takahiko TANIGUCHI, Akira KAWADA, Mitsuyo KONDO, John F. QUINN, Jun KUNITOMO, Masato YOSHIKAWA, Makoto FUSHIMI